Effectiveness of Erlotinib in Advanced Non-Small Cell Lung Cancer in Cases of Gefitinib Resistance after Treatment of More Than 6 Months

Publisher： Karger

E-ISSN： 2296-5262|35|1-2|18-22

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.35, Iss.1-2, 2012-01, pp. : 18-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erlotinib after Failure of Gefitinib Treatment of More Than 6 Months in Advanced Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 1-2, 2012-01 ,pp. : 8-9

Karger

Access to resources Recommend Favorite

Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-09 ,pp. : 464-466

Karger

Access to resources Recommend Favorite

Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

By  

Oncology, Vol. 79, Iss. 5-6, 2011-04 ,pp. : 423-429

Karger

Access to resources Recommend Favorite

Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer

By  

Reviews on Recent Clinical Trials, Vol. 12, Iss. 1, 2017-01 ,pp. : 51-58

Bentham Science Publishers

Access to resources Recommend Favorite

Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 2, 2014-08 ,pp. : 182-191

John Wiley & Sons Inc

Access to resources Recommend Favorite